Diethylstilbestrol Female Raw Steroid Powders Stilboestrol Atovaquone 56-53-1
- Fabricante: Dewael
- Ensaio do produto: 99%+
- Aparência:Pó cristalino branco ou quase branco
- Lugar de origem: China
- Certificação: SGS,ISO9001, GMP
- Quantidade mínima de encomenda: 10g
- Detalhes de empacotamento: formas discretas de embalagem para Customs passagem garantida
- Tempo de entrega: Dentro 12 horas após o recebimento do pagamento
- Termos de pagamento: Western Union, MoneyGram,Bitcoin,Transferência bancária
- Remessa: EMS,DHL,Fedex,UPS,TNT e assim por diante.
- Política: Re-envio Política
- Capacidade de fornecimento: 500-600kg / mês
Diethylstilbestrol Female Raw Steroid Powders Stilboestrol Atovaquone 56-53-1
1.Informações básicas.
Nome do Produto: Dietilestilbestrol
English Name: Stilboestrol; Atovaquone ; diethylstilbestrol, mixture of cis and trans;; Dietilestilbestrol, mixture of cis and trans; Diethylstilbestrol BP
CAS: 56-53-1; 6898-97-1
EINECS Number: 200-278-5
Formula: C18H20O2
MW: 268.3502
Estrutura Molecular:
Densidade: 1.107g / cm3
Ponto de fusão: 169-175 ºC
Boiling point: 407.1 ° C at 760 mmhg
Ponto de inflamação: 187 ° C
Water-soluble: PRACTICALLY INSOLUBLE
Vapor Pressure: 3.29E-07mmHg at 25 ° C
Uses:It belongs hormone drugs
Ensaio:99.29%
Aparência:white crystal powders.
2.Descrição
Dietilestilbestrol (DES, former BAN stilboestrol) is a synthetic nonsteroidal estrogen that was first synthesized in 1938. It is also classified as an endocrine disruptor. Human exposure to DES occurred through diverse sources, such as dietary ingestion from supplemented cattle feed and medical treatment for certain conditions, including breast and prostate cancers.
From about 1940 para 1971, DES was given to pregnant women in the mistaken belief it would reduce the risk of pregnancy complications and losses.
In 1971, DES was shown to cause a rare vaginal tumor in girls and women who had been exposed to this drug in utero. The United States Food and Drug Administration subsequently withdrew DES from use in pregnant women. Follow-up studies have indicated that DES also has the potential to cause a variety of significant adverse medical complications during the lifetimes of those exposed.
The United States National Cancer Institute recommends women born to mothers who took DES undergo special medical exams on a regular basis to screen for complications as a result of the drug. Individuals who were exposed to DES during their mothers’ pregnancies are commonly referred to as “DES daughters” e “DES sons”.
3.Aplicação:
Diethylstilbestrol is a synthetic, nonsteroidal estrogen.Recomended solvents are DMSO, DMF and ethanol, even in these solvents do not store in solution for any prolonged period of time.A synthetic, nonsteroidal estrogen. Recomended solvents are DMSO, DMF and ethanol, even in these solvents do not store in solution for any prolonged period of time.Mainly used for low disease and estrogen hormone imbalance caused by functional bleeding, amenorrhea, can also be used before induction of labor stillbirth to increase myometrial oxytocin sensitivity of the Tunica muscularis.
Women who used DES themselves have a slightly increased risk of breast cancer-approximately 30 percent higher than that of women who did not take DES (14). Women who used DES also have a 30 percent higher risk of death from breast cancer than unexposed women (15). This risk has been found to be stable over time-that is, it does not increase as the mothers become older. No evidence exists to suggest that women who took DES are at higher risk for any other type of cancer.
4. Uso:
A synthetic, nonsteroidal estrogen. Recomended solvents are DMSO, DMF and ethanol, even in these solvents do not store in solution for any prolonged period of time. Mainly used for low disease and estrogen hormone imbalance caused by functional bleeding, amenorrhea, can also be used before induction of labor stillbirth to increase myometrial oxytocin sensitivity of the Tunica muscularis.
———————————————————————————————————————————————————————————————————————————————————————-
Contate agora
Rever
Não há comentários ainda.